McKesson Corporation vs Snap On Incorporated — how do they compare? McKesson Corporation trades at $930 (market cap $108.46B), while Snap On Incorporated trades at $358.97 (market cap $18.56B). The key difference: McKesson Corporation is far larger — about 5.8× Snap On Incorporated's market cap, and Snap On Incorporated pays the higher dividend (2.72%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Snap On Incorporated for 36 Days on average.
| MCK | SNA | |
|---|---|---|
Market Cap | $108.46B | $18.56B |
Volume | 712,607 | 401,326 |
Sector | Health | Industrials |
52-Week High | $995.69 | $419.31 |
52-Week Low | $725.17 | $327.33 |
Typical Hold Time | 74 Days | 36 Days |
Enterprise Value | $115.00B | $18.20B |
Dividend Yield | 0.4% | 2.72% |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
Snap-On Incorporated (SNA) trades at $359.89, down 2.37% on the day, with technical indicators showing bearish momentum despite strong fundamentals. The company maintains robust profitability with 19.6% net margins and 17.58% ROE, supported by consistent earnings beats in recent quarters. Analyst consensus remains bullish with a $449 price target, representing 25% upside potential from current levels.
SNA offers attractive fundamentals with expanding gross margins and solid cash flow generation, though technical weakness and premium valuation present near-term headwinds. The stock's investment case hinges on continued execution of RCI initiatives and diagnostic segment growth, balanced against valuation concerns and mixed technical signals.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →